Edgar G. Engleman

Dr. Ed Engleman is professor of pathology and medicine at Stanford University School of Medicine, where he oversees the Stanford Blood Center and his own immunology research group. He is also co-director of the Immunology and Immunotherapy Program of the Stanford Cancer Institute. Dr. Engleman has authored more than 300 publications in medical and scientific journals and has trained more than 100 graduate students and postdoctoral scholars, many of whom have gone on to successful careers in industry and academia. Dr. Engleman is a co-founder and managing partner of Vivo Capital, a leading healthcare focused investment firm with offices in the U.S. and Asia. He has also co-founded a number of biopharmaceutical companies including Genelabs, Dendreon, Medeor and Tranquis. He is the lead inventor of the technology underlying Sipuleucel-T (Provenge), which was shown to extend life for patients with metastatic prostate cancer and was the first active immunotherapeutic agent to be approved by the FDA. Recently, Dr. Engleman’s laboratory discovered a promising new immunotherapy that activates dendritic cells in tumors in situ without requiring their removal and activation in vitro. This treatment was shown to eradicate a wide range of tumors in mouse models and provided the basis for the creation of Bolt Biotherapeutics. Dr. Engleman currently serves on the boards of several private biotechnology companies including Bolt. He received his B.A. from Harvard University and his M.D. from Columbia University School of Medicine.